Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Johan Richter; Anna Lubking; Stina Soderlund; Kourosh Lotfi; Berit Markevarn; Anders Sjalander; Leif Stenke; Stefan Deneberg; Erik Ahlstrand; Kristina Myhr-Eriksson; Panayiotis Panayiotidis; Tobias Gedde-Dahl; Daniela Zackova; Jiri Mayer; Ulla Olsson-Stromberg; Francois-Xavier Mahon; Susanne Saussele; Henrik Hjorth-Hansen; Perttu Koskenvesa

doi:10.1038/s41375-021-01173-w

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Johan Richter, Anna Lubking, Stina Soderlund, Kourosh Lotfi, Berit Markevarn, Anders Sjalander, Leif Stenke, Stefan Deneberg, Erik Ahlstrand, Kristina Myhr-Eriksson, Panayiotis Panayiotidis, Tobias Gedde-Dahl, Daniela Zackova, Jiri Mayer, Ulla Olsson-Stromberg, Francois-Xavier Mahon, Susanne Saussele, Henrik Hjorth-Hansen, Perttu Koskenvesa

Tutkimustuotos: Artikkelijulkaisu › Kirje › Tieteellinen

Alkuperäiskieli	englanti
Lehti	Leukemia
Vuosikerta	35
Numero	8
Sivut	2416-2418
Sivumäärä	3
ISSN	0887-6924
DOI - pysyväislinkit	https://doi.org/10.1038/s41375-021-01173-w
Tila	Julkaistu - elok. 2021
OKM-julkaisutyyppi	B1 Kirjoitus tieteellisessä aikakauslehdessä

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.1038/s41375-021-01173-w

s41375-021-01173-wLopullinen julkaistu versio, 297 KBLisenssi: CC BY

Siteeraa tätä

Richter, J., Lubking, A., Soderlund, S., Lotfi, K., Markevarn, B., Sjalander, A., Stenke, L., Deneberg, S., Ahlstrand, E., Myhr-Eriksson, K., Panayiotidis, P., Gedde-Dahl, T., Zackova, D., Mayer, J., Olsson-Stromberg, U., Mahon, F-X., Saussele, S., Hjorth-Hansen, H., & Koskenvesa, P. (2021). Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia, 35(8), 2416-2418. https://doi.org/10.1038/s41375-021-01173-w

@article{2d297d5ebf894dbfb9e9a5bf99588f5a,

title = "Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI",

keywords = "3122 Cancers",

author = "Johan Richter and Anna Lubking and Stina Soderlund and Kourosh Lotfi and Berit Markevarn and Anders Sjalander and Leif Stenke and Stefan Deneberg and Erik Ahlstrand and Kristina Myhr-Eriksson and Panayiotis Panayiotidis and Tobias Gedde-Dahl and Daniela Zackova and Jiri Mayer and Ulla Olsson-Stromberg and Francois-Xavier Mahon and Susanne Saussele and Henrik Hjorth-Hansen and Perttu Koskenvesa",

year = "2021",

month = aug,

doi = "10.1038/s41375-021-01173-w",

language = "English",

volume = "35",

pages = "2416--2418",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "8",

}

Richter, J, Lubking, A, Soderlund, S, Lotfi, K, Markevarn, B, Sjalander, A, Stenke, L, Deneberg, S, Ahlstrand, E, Myhr-Eriksson, K, Panayiotidis, P, Gedde-Dahl, T, Zackova, D, Mayer, J, Olsson-Stromberg, U, Mahon, F-X, Saussele, S, Hjorth-Hansen, H & Koskenvesa, P 2021, 'Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI', Leukemia, Vuosikerta 35, Nro 8, Sivut 2416-2418. https://doi.org/10.1038/s41375-021-01173-w

TY - JOUR

T1 - Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

AU - Richter, Johan

AU - Lubking, Anna

AU - Soderlund, Stina

AU - Lotfi, Kourosh

AU - Markevarn, Berit

AU - Sjalander, Anders

AU - Stenke, Leif

AU - Deneberg, Stefan

AU - Ahlstrand, Erik

AU - Myhr-Eriksson, Kristina

AU - Panayiotidis, Panayiotis

AU - Gedde-Dahl, Tobias

AU - Zackova, Daniela

AU - Mayer, Jiri

AU - Olsson-Stromberg, Ulla

AU - Mahon, Francois-Xavier

AU - Saussele, Susanne

AU - Hjorth-Hansen, Henrik

AU - Koskenvesa, Perttu

PY - 2021/8

Y1 - 2021/8

KW - 3122 Cancers

U2 - 10.1038/s41375-021-01173-w

DO - 10.1038/s41375-021-01173-w

M3 - Letter

VL - 35

SP - 2416

EP - 2418

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -